Related medicinesEpidermal growth factorCetuximabPanitumumabErlotinibOsimertinib
Where it comes from
- Made in
- Salivary glands, duodenal Brunner’s glands, kidney and milk; also platelets
- Sent out by
- Into saliva, gut, urine and milk; cut from its precursor by proteases
- Acts on
- Epithelial cells of skin and gut
- Fibroblasts
- Tumours with EGFR
What it does
- Drives epithelial cells to divide and move, closing wounds
- Protects and repairs the gut lining; it was first known as urogastrone, found in urine as an inhibitor of gastric acid before the two were shown to be the same peptide 4
- Supports the growth of a newborn’s gut, from milk
In medicine
- Recombinant human EGF is approved in several countries, Cuba, China and Korea among them, for diabetic foot ulcers and burns: injected into the ulcer in Cuba 1, sprayed onto it in Korea, where a phase 3 trial healed 73 per cent of ulcers against 51 per cent on placebo 2. It is approved in neither the United States nor the European Union
- EGFR blockers work the other way round and treat cancer: cetuximab, panitumumab, erlotinib, osimertinib and the rest
- EGF enemas were tested in 24 people with left-sided ulcerative colitis: 10 of 12 on EGF were in remission at two weeks against 1 of 12 on placebo 3
Beyond the body’s own use
- EGF is a common ingredient in skin creams. The trials behind that use are small and short, and a protein of this size crosses intact skin poorly, so how much reaches a living cell is unclear
- In the gut it is still being studied: the enema result in ulcerative colitis has not been repeated in a larger trial in twenty years, and the EGF in milk is studied for the protection of the premature intestine 3
Sources
- Fernández-Montequín et al., Intralesional recombinant human EGF in advanced diabetic foot ulcers, International Wound Journal 2009
- Park et al., Topical epidermal growth factor spray for chronic diabetic foot ulcers, Diabetes Research and Clinical Practice 2018
- Sinha et al., Epidermal growth factor enemas in left-sided ulcerative colitis, New England Journal of Medicine 2003
- Gregory, Isolation and structure of urogastrone and its relationship to epidermal growth factor, Nature 1975
This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.